Total revenue was USD 53.23 million, up 2% from USD 52.29 million. Product revenue was USD 37.16 million against USD 38.11 million, a decrease of 3%, while service revenue was USD 16.07 million against USD 14.18 million, an increase of 13% that the company …
Net sales rose 11.7%, and the company broke the change into three parts: a USD 50.0 million, or 11.2%, benefit from the Antares Vision acquisition, organic growth of USD 4.9 million, or 1.1%, driven by the Currency business, and a currency translation effect of …
Four facilities were sold to the Department of Homeland Security on July 2 and August 4, producing a gain of USD 1,770.7 million. Gross proceeds were USD 2.2 billion and net proceeds after income taxes andTransaction Costswere about USD 1.6 billion. The company continues …
MYQORZO (aficamten) was approved by the FDA in December 2025 and became available to patients around January 27, 2026. The European Commission approved it in February 2026, the United Kingdom granted aMarketingauthorization in July, and Health Canada issued a Notice of Compliance in October. …
The company attributed the growth in service fees to an approximate 18% increase in average monthly transacting Members, ExtraCash originations of approximately USD 2.5 billion against approximately USD 2.0 billion, and an average ExtraCash amount of USD 218 against USD 207. It also cited …
The company said it does not see significant additional restructuring charges in 2026 from the 2025 Restructuring Plan, which it adopted in response to macroeconomic pressures. It also completed two divestitures from the Industrial Solutions segment: Geomagic, sold on April 1, 2025 for USD …
Total revenue was USD 108.5 million against USD 499.8 million in the third quarter of 2025. Derivatives produced a loss of USD 378.4 million against a gain of USD 111.0 million a year earlier. Commodity revenue was USD 469.6 million against USD 372.8 million.
ClearanceJobs revenue reached USD 16.507 million, against USD 13.937 million a year earlier, an increase of 18%. The company attributed the gain to continuedDemandfor professionals with government security clearance, consistent product releases and theAcquisitionof Point Solutions Group. Dice revenue was USD 15.733 million, against …
The CEO said revenue across the combined Payments and Data businesses grew by over 21%. Merchant Services revenue was USD 135.1 million against USD 98.0 million a year earlier, B2B Payments was USD 77.3 million against USD 73.1 million, and Data Solutions was USD …
The company develops antibody therapies for blood disorders driven by mutant calreticulin, with three candidates: DMR-001, DMR-002 and DMR-003. It began the CLARITY-101 trial of DMR-001 in essential thrombocythemia and myelofibrosis patients after receiving health authority approval in Australia, and it has since received …